Status:
RECRUITING
AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT)
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
Center for Medicinal Cannabis Research
Conditions:
Pain
Appetite Loss
Eligibility:
All Genders
21-55 years
Phase:
PHASE1
Brief Summary
This study will assess the analgesic, appetite-stimulating, and subjective effects of cannabigerol (CBG) alone and in combination with THC.
Detailed Description
The overall aim of this double-blind, placebo-controlled, within-subject study in healthy, occasional cannabis smokers is to ascertain the dose-dependent analgesic and appetite-stimulating effects of ...
Eligibility Criteria
Inclusion
- Male or non-pregnant and non-lactating females aged 21-55 years
- • Report occasional use of cannabis (cannabis use between ≥ biweekly and ≤ 3 days per week) over the month prior to screening
- Not currently seeking treatment for their cannabis use
- Have a Body Mass Index from 18.5 - 34kg/m2.
- Able to perform all study procedures
- Must be using a contraceptive (hormonal or barrier methods)
- Females must not be lactating
Exclusion
- Meeting DSM-V criteria for moderate-severe Cannabis Use disorder (CUD) or any substance use disorder other than nicotine, caffeine, or mild CUD
- Any other Axis I disorder
- • Current use of any medications within 14 days or 5 half-lives of administration (whichever is longer) except for hormonal contraceptives in females. If a medication is taken once a participant is enrolled, sessions will be suspended for 14 days or 5 half-lives after administration (whichever is longer)
- If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures.
- Current pain
- Pregnancy is exclusionary due to the possible effects of the study medication on fetal development.
- History of an allergic reaction or adverse reaction to cannabis is exclusionary.
- History of respiratory illness or current respiratory illness
- Currently enrolled in another research protocol
- Not using a contraceptive method (hormonal or barrier methods)
- Insensitivity to the cold water stimulus of the Cold Pressor Test
- Any disorders that might make cannabis administration hazardous are exclusionary, as determined by the evaluating physician
Key Trial Info
Start Date :
February 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 22 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04859296
Start Date
February 15 2023
End Date
December 22 2026
Last Update
August 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles
Los Angeles, California, United States, 90095